NY-EMPIRE-STATE-REALTY
13.2.2024 23:24:29 CET | Business Wire | Press release
Be an ESB VIP. The Empire State Building (ESB) announced today its new ambassador program for locals who host guests in New York City and superfans of its world-famous Observatory Experience. Visitors earn points in the loyalty program for each ticket purchased on the ESB website for the 86th and 102nd Floor Observatories and redeem them for complimentary experiences and collectibles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240213973067/en/
Rewards to include exclusive NFTs, complimentary tickets, and special experiences. (Photo: Business Wire)
“Each visit to the Empire State Building is unique, and we made it easier for our loyal locals who bring their guests and our superfans to take in our reimagined Observatory’s exhibits and unparalleled views time and time again,” said Jean-Yves Ghazi, president of the Empire State Building Observatory. “We want to show our fans our appreciation for their loyalty and offer exclusive access to premium, authentic experiences and the best views from the heart of New York City.”
Members will progress through four tiers and collect rewards at each tier which include:
-
Ambassador (Unlocked at 0-439 points)
- Has registered for the program
- Not yet eligible for any benefits
-
Bronze Ambassador (Unlocked at 440 points)
- Inclusion in our Ambassadors’ Newsletter
- One ticket to the 86th Floor Observatory
- One lottery entry for access for two (2) guests to one of the exclusive ESB influencer or celebrity appearances events. Non-transferable.
-
Silver Ambassador (Unlocked at 880 points)
- Inclusion in our Ambassadors’ Newsletter
- One additional ticket to the 86th Floor Observatory
- One additional lottery entry for access for two (2) guests to one of the exclusive ESB influencer or celebrity visit events. Non-transferable.
-
Gold Ambassador (Unlocked at 1,320 points)
- Inclusion in our Ambassadors’ Newsletter
- Two tickets to the 86th and 102nd Floor Observatories
- Two tickets to a scheduled Saturday morning Sunrise Experience
- Two entries to the coveted annual Empire State Building Run-Up (assignable to a family member or friend) or lottery entry for access for two (2) guests to one of the exclusive ESB influencer or celebrity visit events. Non-transferable.
-
Platinum Ambassador (Unlocked at 1,760 points)
- Inclusion in our Ambassadors’ Newsletter
- Four tickets to the 86th and 102nd Floor Observatories
- Four tickets to a scheduled Saturday morning Sunrise Experience
- One entry to the coveted annual Empire State Building Run-Up (assignable to a family member or friend).
- Entry for access for four (4) guests to one of the exclusive ESB influencer or celebrity visit events. Non-transferable
Each new member of the Ambassador Program will receive a custom NFT upon signup. For each tier achieved, members will receive additional custom NFTs, developed and distributed in partnership with Uptop, which feature the “World’s Most Famous Building” against an Art Deco backdrop in the tier’s respective metallic tone. The exclusive NFTs serve as a digital keepsake and a key to unlock their personalized rewards.
Visitors who join the Ambassador Program who purchased tickets on or after Feb. 1, 2024 will automatically receive points and the new member NFT for their last purchase retroactively. Points and status acquired remain until redemptions and do not expire.
The Empire State Building Observatory recently underwent a $165 million reimagination that includes a dedicated visitor entrance, an immersive museum with nine galleries, brand new bespoke Observatory Host uniforms, and iconic 86th and 102nd Floor Observatories. The reimagined Observatory Experience was recently voted the number one attraction in the U.S. by Tripadvisor travelers for two consecutive years.
Registration for the Ambassador Program can be found here.
Hi-res imagery can be found here. More information about the Empire State Building Observatory can be found online.
About the Empire State Building
The Empire State Building, the “World's Most Famous Building," owned by Empire State Realty Trust, Inc. (ESRT: NYSE), soars 1,454 feet above Midtown Manhattan from base to antenna. The $165 million reimagination of the Empire State Building Observatory Experience creates an all-new experience with a dedicated guest entrance, an interactive museum with nine galleries, and a redesigned 102nd Floor Observatory with floor-to-ceiling windows. The journey to the world-famous 86th Floor Observatory, the only 360-degree, open-air observatory with views of New York and beyond, orients visitors for their entire New York City experience and covers everything from the building's iconic history to its current place in pop culture. The Empire State Building Observatory Experience welcomes millions of visitors each year and was declared "America's Favorite Building" by the American Institute of Architects, the world's most popular travel destination by Uber, the #1 attraction in the US for the second year in a row in Tripadvisor’s 2023 Travelers’ Choice Awards: Best of the Best, and the #1 New York City attraction in Lonely Planet’s Ultimate Travel List.
Since 2011, the building has been fully powered by renewable wind electricity, and its many floors house a diverse array of office tenants such as LinkedIn and Shutterstock, as well as retail options like STATE Grill and Bar, Tacombi, and Starbucks. For more information and Observatory Experience tickets visit esbnyc.com or follow the building's Facebook, X (formerly Twitter), Instagram, Weibo, YouTube, or TikTok.
Source: Empire State Realty Trust, Inc.
Category: Observatory
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240213973067/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
